Investor Relations :: Molecular Templates, Inc. (MTEM)

Latest News

Molecular Templates, Inc. to Present Interim Results on MT-5111 at the 45th Annual San Antonio Breast Cancer Symposium (SABCS) and Participate at the 64th American Society of Hematology (ASH) Annual Meeting

Dec 2, 2022

Molecular Templates, Inc. to Present Fireside Chats at Two Upcoming Investor Conferences: Evercore ISI’s 5th Annual HealthCONx Conference and Piper Sandler’s 34th Annual Healthcare Conference

Nov 23, 2022

Molecular Templates, Inc. Reports Third Quarter 2022 Financial Results

Nov 10, 2022

View All News

San Antonio Breast Cancer Symposium 2022
A phase 1 study of the novel immunotoxin MT-5111 in patients with HER2+ tumors: interim results

Q3 2022

Quarter Ended Sep 30, 2022

Earnings Release

10-Q

PDF HTML

XBRL

ZIP XLS HTML

Latest Annual Filing

For Fiscal Year Ending December 31, 2021

Company Overview

Molecular Templates is focused on the discovery, development, and commercialization of next-generation immunotoxins called Engineered Toxin Bodies (ETBs) for the treatment of cancers and other serious diseases.

View Management Team View Board of Directors

Investor Contact Information

Company

Molecular Templates, Inc.
9301 Amberglen Blvd
Suite 100
Austin, TX 78729

Investor Relations

Dr. Grace Kim
grace.kim@mtem.com

Transfer Agent

Computershare
PO Box 358015
Pittsburgh, PA 15252
T: 781-575-3120